From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.
Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.
From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.
AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.